ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "COVID-19"

  • Abstract Number: 0006 • ACR Convergence 2020

    Race/ethnicity Is Associated with Poor Health Outcomes Amongst Rheumatic Disease Patients Diagnosed with COVID-19 in the US: Data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry

    Milena Gianfrancesco1, Liza Leykina2, Zara Izadi3, Carly Harrison4, Suleman Bhana5, Wendy Costello6, Rebecca Grainger7, Jonathan Hausmann8, Jean Liew9, Emily Sirotich10, Paul Sufka11, Zachary Wallace12, Gabriela Schmajuk13, Pedro M Machado14, Philip Robinson15 and Jinoos Yazdany16, 1University of California, San Francisco, San Francisco, CA, 2UCSF, San Francisco, 3University of California San Francisco, San Francisco, CA, 4Lupus Chat, NA, 5Crystal Run Health, Middletown, 6Irish Children's Arthritis Network, Tipperary, Ireland, 7University of Otago, Wellington, New Zealand, 8Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 9University of Washington, Seattle, WA, 10McMaster University, Hamilton, ON, Canada, 11Healthpartners, St Paul, 12Massachusetts General Hospital, Newton, MA, 13University of California, San Francisco, Atherton, CA, 14University College London, London, United Kingdom, 15University of Queensland, Herston, Queensland, Australia, 16UCSF, San Francisco, CA

    Background/Purpose: Individuals with rheumatic disease, particularly those on immunosuppressive medications, have a higher risk of developing severe infections. However, whether these patients experience more severe…
  • Abstract Number: 0050 • ACR Convergence 2020

    Demographic Disparities in the Medically Underserved Populations of Southern California: A Rheumatology Cohort of Cytokine Release Syndrome Patients Due to COVID-19

    Muntarin Karim1, Patil Injean2, Sandy Lee2, Neha Chiruvolu3, Loomee Doo4, Deepa Panikkath2, Donna Jose5, Micah Yu4, Anna Lafian4, Vaneet Sandhu6, Karina Torralba7, Christina Downey2, Mehrnaz Hojjati4 and Marven Cabling4, 1Loma Linda University Health System, Loma Linda, CA, 2Loma Linda University Medical Center, Redlands, CA, 3UC Riverside School of Medicine, Riverside, CA, 4Loma Linda University Medical Center, LOMA LINDA, CA, 5Loma Linda University Medical Center, Ontario, CA, 6Loma Linda University, Loma Linda, CA, 7Loma Linda University School of Medicine, Redlands, CA

    Background/Purpose: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the present coronavirus disease (COVID-19) pandemic. Multiple epidemiologic reports across the country show…
  • Abstract Number: 0466 • ACR Convergence 2020

    Dosage Modification of Immunomodulatory Medications by Rheumatology Patients in New York City During the Peak of the COVID-19 Pandemic

    Marianna Frey1, Gregory Vitone2, Candace Feldman3, Lindsay Lally1, Anne Bass4, Jane Salmon1, Mary Crow1, Michael Lockshin5, Vivian Bykerk1, Lisa Mandl1 and Medha Barbhaiya5, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, 3Brigham and Women's Hospital, Boston, 4Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 5Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY

    Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases living in COVID-19 “hot spots” may have modified their immunomodulatory…
  • Abstract Number: 0613 • ACR Convergence 2020

    Modeling the Effects of Covid-19 Protective Behaviors and Healthcare Delivery on the Health of Patients with Rheumatic Disease

    Kevin Kennedy1, Emily Sirotich2, Salman Surangiwala3, Maggie Larche2, Mitchell Levine1 and Jonathan Hausmann4, 1McMaster University, Hamilton, Canada, 2McMaster University, Hamilton, ON, Canada, 3Queen’s School of Medicine, Kingston, Canada, 4Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA

    Background/Purpose: COVID-19 has caused global disruptions in the management of chronic illnesses. The extent to which patients with rheumatic disease have been affected by COVID-19…
  • Abstract Number: 0949 • ACR Convergence 2020

    SLAMF7 Engagement Drives Monocyte Super-Activation in Acute and Chronic Inflammation

    Daimon Simmons1, Hung Nguyen2, Emma Gomez-Rivas3, YunJu Jeong4, William Apruzzese5, Edy Kim6 and Michael Brenner7, 1Department of Pathology, Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Brigham and Women's Hospital,, Boston, MA, 3Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, 4Division of Pulmonary and Critical Care, Brigham and Women's Hospital, Boston, MA, 5., Boston, 6Brigham and Women’s Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Monocytes orchestrate immune responses that protect against microbes but can also drive pathological inflammation and autoimmune disease. Monocytes are thought to be activated primarily…
  • Abstract Number: 1478 • ACR Convergence 2020

    A Multidisciplinary Registry of Patients with Autoinmune and Immune-Mediated Diseases with Symptomatic COVID-19 Infection from a Single Center

    Juan C Sarmiento-Monroy1, Gerard Espinosa2, Fernanda Meira1, Berta Caballol3, Maria C Londoño3, Sara Llufriu3, Aina Moll1, Luis Fernando Quintana Porras1, Felipe Julio Ramirez Garcia4, José Inciarte-Mundo1, Elisabeth Solana1, Yolanda Blanco1, Eugenia Martinez1, Victor Llorens1, Sergio Prieto-González5, Georgina Espigol1, Jose C Milisenda1, Maria C. Cid5, Priscila Giavedoni1, Jose M Mascaró1, Isabel Blanco1, Joan Albert Barbera1, Oriol Sibila1, Jordi Gratacos-Gines1, Alfredo Adan2, Alvaro Agustí1, Raimon Sanmartí6, Julián Panés1, Ricard Cervera1, Jordi Vila1, Alex Soriano1, Jose Gómez-Puerta6 and On behalf INMUNOCOVID CLINIC7, 1Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 2Hospital Clinic, Barcelona, Catalonia, Spain, 3Hospital Clinic de Barcelona, Barcelona, Spain, 4Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain, Barcelona, Catalonia, Spain, 5Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, 6Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, 7Hospital Clinic de Barcelona, Barcelona

    Background/Purpose: National health authorities reported a prevalence of SARS-CoV-2 infection around 7% of the general population in Barcelona county (1). A recent report focused on…
  • Abstract Number: 0007 • ACR Convergence 2020

    Antimalarial Drug Shortages During the COVID-19 Pandemic: Results from the Global Rheumatology Alliance Patient Experience Survey

    Emily Sirotich1, Kevin Kennedy2, Salman Surangiwala3, Teresa Semalulu1, Maggie Larche1, Jean Liew4, Zachary Wallace5, Philip Robinson6, Rebecca Grainger7, Jeffrey Sparks8, Julia Simard9, Jinoos Yazdany10, Monique Gore-Massy11, Richard Howard12, Mitchell Levine2 and Jonathan Hausmann13, 1McMaster University, Hamilton, ON, Canada, 2McMaster University, Hamilton, Canada, 3Queen’s School of Medicine, Kingston, Canada, 4University of Washington, Seattle, WA, 5Massachusetts General Hospital, Newton, MA, 6University of Queensland, Herston, Queensland, Australia, 7University of Otago, Wellington, New Zealand, 8Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 9Stanford Medicine, Stanford, CA, 10UCSF, San Francisco, CA, 11Lupus Foundation of America, Brooklyn, NY, 12Spondylitis Association of America, Van Nuys, CA, 13Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA

    Background/Purpose: Early in the COVID-19 pandemic, hydroxychloroquine and chloroquine were empirically promoted and used for treatment and prevention of SARS-CoV-2 infection. The repurposing of these…
  • Abstract Number: 0051 • ACR Convergence 2020

    COVID-Related Distress and Mental Health in Adult Rheumatology Patients During the COVID-19 Pandemic

    Shereen Mahmood1, Laura Curiel-Duran2, Ruchika Darapaneni2, Dalynah Maldonado2, Lindsay Pattison2, Emilee Tu2 and Tamar Rubinstein3, 1Albert Einstein College of Medicine / Montefiore Medical Center, Wantagh, NY, 2Albert Einstein College of Medicine / Montefiore Medical Center, Bronx, NY, 3Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY

    Background/Purpose: The novel coronavirus disease 2019 (COVID-19) pandemic has significantly affected all aspects of society, especially in the epicenters of New York City (NYC) and…
  • Abstract Number: 0467 • ACR Convergence 2020

    Incidence of COVID-19 in Patients Treated with Infliximab Compared to Patients Treated with Rituximab

    Cathy Melong Pianta1, Kim Lauper1, Delphine Courvoisier1, Tim Cunningham2, Daniéle Allali3 and Axel Finckh4, 1Division of rheumatology, Geneva University Hospitals, Geneva, Switzerland, 2Private practice, Geneva, Geneva, Switzerland, 3Division of immunology, Geneva University Hospitals, Geneva, 4Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland

    Background/Purpose: The prevalence of anti-SARS-CoV-2 IgG infection was estimated at 9.7% in the Geneva population end of April 2020. (1) Immunosuppressed patients may be at…
  • Abstract Number: 0614 • ACR Convergence 2020

    Impact of COVID-19 Pandemic on the Rheumatology Practice in Mexico: Mexican College of Rheumatology Survey

    Natllely Ruiz1, José Enrique Ruiz Guizar2, Erick A Zamora Tehozol3, Iris Jazmín Colunga Pedraza4, Cristina Hernández-Díaz5, Vijaya Rivera-Terán6, Cesar Pacheco Tena7 and Deshire Alpizar-Rodriguez6, 1Instituto Nacional de Enfermedades Respiratorias, Mexico City, Distrito Federal, Mexico, 2Independent, Mexico City, Distrito Federal, Mexico, 3Centro Médico Pensiones, Merida, Yucatan, Mexico, 4Rheumatology service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Mexico, 5Instituto Nacional de Rehabilitación, Mexico City, Distrito Federal, Mexico, 6Colegio Mexicano de Reumatología, Mexico City, Distrito Federal, Mexico, 7Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico

    Background/Purpose: COVID-19 pandemic is an evident challenge for healthcare systems and daily clinical practice in developing countries. Particularly, chronic diseases attention has faced difficulties. The…
  • Abstract Number: 0984 • ACR Convergence 2020

    Neighborhood Deprivation and Race/Ethnicity Affects COVID-19 Risk and Severity in SLE

    Ashira Blazer1, Ruth Fernandez-Ruiz2, Mala Masson2, Rebecca Haberman3, Rochelle Castillo4, Jose Scher4, Huda Algasas5, Allison Guttmann2, Philip Carliucci3, Kristina Deonaraine2, Michael Golpanian6, Kimberly Robins2, Miao Chang2, H. Michael Belmont6, Jill Buyon7, Amit Saxena3 and Peter Izmirly6, 1NYU School of Medicine, New York, NY, 2New York University School of Medicine, New York, 3NEW YORK UNIVERSITY SCHOOL OF MEDICINE, New York, NY, 4NYU School of Medicine, New York City, 5Columbia University, New York, NY, 6New York University, New York, NY, 7Department of Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: Disparities have been reported during the coronavirus disease (COVID-19) outbreak. Systemic lupus erythematosus (SLE) patients represent a unique group that is affected by clinical,…
  • Abstract Number: 1497 • ACR Convergence 2020

    COVID-19 in Pregnant Patients with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance

    Bonnie Bermas1, Megan Clowse2, Milena Gianfrancesco3, Jonathan Hausmann4, Pedro M Machado5, Emily Sirotich6, Helen Robinson7, Anja Strangfeld8, Jinoos Yazdany9 and Philip Robinson10, 1UTSouthwestern.edu, Dallas, TX, 2Duke University, Chapel Hill, NC, 3University of California, San Francisco, San Francisco, CA, 4Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 5University College London, London, United Kingdom, 6McMaster University, Hamilton, ON, Canada, 7University of Queensland School of Medicine, HERSTON, Queensland, Australia, 8German Rheumatism Research Center, Berlin, Germany, 9UCSF, San Francisco, CA, 10University of Queensland, Herston, Queensland, Australia

    Background/Purpose: The impact of COVID-19 on pregnancy in patients with rheumatic disease is unknown. We describe COVID-19 outcomes in pregnant rheumatic disease patients reported to…
  • Abstract Number: 0008 • ACR Convergence 2020

    COVID-19 Infection Among Patients with Rheumatic Disease on Biologic & Targeted Therapies: A Systematic Review

    Akhil Sood1, Arbi Galestanian1, Vijaya Murthy2, Emilio Gonzalez1 and Mukaila Raji1, 1University of Texas Medical Branch, Galveston, TX, 2University of Texas Medical Branch, League City, TX

    Background/Purpose: Information about the outcomes of patients with rheumatic disease with SARS-CoV-2 infection is scarce. Patients with rheumatic disease on immunosuppressive medications might represent a…
  • Abstract Number: 0069 • ACR Convergence 2020

    Identification of CD13 as a Potential Cause for SARS-CoV-2-triggered Hyperinflammation and Thrombosis

    Eliza Pei-Suen Tsou1, Gautam Sule1, Mikel Gurrea Rubio2, M. Asif Amin1, Yu Zuo1, Jason Knight1, Yogendra Kanthi3 and David Fox1, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, University of Michigan, Canton, MI, 3Division of Cardiovascular Medicine, Ann Arbor

    Background/Purpose: The ectopeptidase CD13, which is highly expressed on stromal and myeloid cells in joints, lung and other tissues, is a known receptor for many…
  • Abstract Number: 0468 • ACR Convergence 2020

    Concerns and Health-Related Behaviors During the COVID-19 Pandemic in Patients with or Without Autoimmune Rheumatic Disease in a Large Physician Network

    Michael George1, Shilpa Venkatachalam2, Shubhasree Banerjee1, Joshua Baker1, Peter Merkel1, David Curtis3, Kelly Gavigan4, Maria (Maio) Danila5, Daniel Kirby6, George Munoz7, William Sunshine8, William Nowell9 and Jeffrey R Curtis10, 1University of Pennsylvania, Philadelphia, PA, 2Global Healthy Living Foundation, Upper Nyack, 3Global Healthy Living Foundation, New York City, 4Global Healthy Living Foundation, Upper Nyack, NY, 5University of Alabama at Birmingham (UAB), Birmingham, AL, 6AARA, Charlotte, NC, 7AARA, Aventura, FL, 8AARA, Boca Raton, FL, 9Global Healthy Living Foundation, New York City, NY, 10Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Patients with autoimmune rheumatic diseases (ARD) may be particularly concerned about COVID-19. We aimed to compare concerns and health-related behaviors of patients with common…
  • « Previous Page
  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology